ID

10972

Description

NSABP Protocol B-40 - Treatment Form for Docetaxel/Gemcitabine Cycles in Groups 3A and 3B NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1AF9CE89-A16C-4210-E044-0003BA3F9857

Link

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1AF9CE89-A16C-4210-E044-0003BA3F9857

Keywords

  1. 12/18/14 12/18/14 - Martin Dugas
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 6/16/15 6/16/15 -
Uploaded on

June 16, 2015

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

NSABP Protocol B-40 - Treatment Form for Docetaxel/Gemcitabine Cycles in Groups 3A and 3B NCT00408408

No Instruction available.

  1. StudyEvent: NSABP Protocol B-40 - Treatment Form for Docetaxel/Gemcitabine Cycles in Groups 3A and 3B
    1. No Instruction available.
Header
Are data amended
Assessment of Chemotherapy
Total Number of Cycles Given (Docetaxel/Gemcitabine)
Why did treatment end or not begin (Docetaxel/Gemcitabine)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial